Download PDF
Diabetologie und Stoffwechsel 2015; 10(03): 141-147
DOI: 10.1055/s-0035-1553166
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

GLP-1-Rezeptoragonisten in der Therapie des Typ-2-Diabetes

Glykämiekontrolle im direkten VergleichGLP-1 Receptor Agonists in the Treatment of Type 2 DiabetesA Direct Comparison of Glycemic Control
J. Seufert
Further Information

Publication History

Publication Date:
10 July 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Glucagon-like-Peptide-1 (GLP-1)-Rezeptoragonisten sind in der Therapie des Diabetes mellitus Typ 2 zunehmend etabliert. Diese Inkretin-basierten Arzneimittel wirken über die Aktivierung von GLP-1-Rezeptoren. Sie wirken streng Glukose-abhängig insulinotrop und glukagonostatisch und ermöglichen eine effiziente Senkung des HbA1c-Werts bei gleichzeitig geringem Hypoglykämierisiko. Darüber hinaus vermitteln sie über zentralnervöse Mechanismen eine Reduktion des Körpergewichts. Die derzeit zugelassenen sechs GLP-1-Rezeptoragonisten weisen unterschiedliche strukturelle und pharmakokinetische Eigenschaften auf, die eine Unterteilung in kurzwirksame und langwirksame Präparate erlauben. Direkte Vergleichsstudien dieser Substanzen konnten Unterschiede und Gemeinsamkeiten hinsichtlich zentraler therapeutischer Parameter wie der Blutzuckereinstellung, des Hypoglykämierisikos, der Auswirkungen der Therapie auf das Körpergewicht und Substanz-spezifischer Nebenwirkungen herausarbeiten. Diese Ergebnisse können dem Diabetologen dabei helfen, unter sorgfältiger Nutzen-Risiko-Abwägung Präferenzen im Sinne eines individualisierten Therapieansatzes zu definieren.

Abstract

Glucagon-like-peptide-1 (GLP-1) receptor agonists are now established as an integral option for the treatment of type 2 diabetes. These incretin-based substances activate specific GLP-1 receptors, and provide insulinotropic and glucagonostatic actions in a strictly glucose-dependent manner, thus allowing effective control of HbA1c levels with a low risk of hypoglycemia. Moreover, they contribute to weight reduction through actions in the brain. Currently there are six GLP-1 receptor agonists approved in Germany. They demonstrate different structural and pharmacokinetic properties and can be grouped into long-acting and short-acting substances. Several head-to-head trials have revealed differences and similarities regarding key therapeutic parameters such as glycemic control, risk of hypoglycemia, effect on body weight and substance-specific side effects. These results can provide helpful support for the diabetologist in defining preferences for an individualized therapeutic approach, based on a careful risk-benefit-analysis.

Schlüsselwörter

Diabetes mellitus Typ 2 - GLP-1-Rezeptoragonisten - Pharmakokinetik - Head-to-Head-Studien

Key words

type 2 Diabetes - GLP-1 receptor agonists - pharmacokinetics - head-to-head trials
 

  • Literatur

  • 1 Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013; 17: 819-837
    CrossrefPubMedGoogle Scholar
  • 2 Seufert J, Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab 2014; 16: 673-688
    CrossrefGoogle Scholar
  • 3 Lund A, Knop FK, Vilsboll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med 2014; 25: 407-414
    CrossrefGoogle Scholar
  • 4 Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705
    CrossrefPubMedGoogle Scholar
  • 5 Lyxumia® (Lixisenatid) in Deutschland außer Vertrieb. , Pressemitteilung der Sanofi Aventis Deutschland GmbH vom 15.03.2014
    Google Scholar
  • 6 Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-742
    CrossrefGoogle Scholar
  • 7 Bush MA, Matthews JE, De Boever EH et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 2009; 11: 498-505
    CrossrefGoogle Scholar
  • 8 Kuritzky L, Umpierrez G, Ekoe JM et al. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad Med 2014; 126: 60-72
    CrossrefGoogle Scholar
  • 9 Christensen M, Knop FK, Holst JJ et al. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs 2009; 12: 503-513
    Google Scholar
  • 10 Gallwitz B. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Int J Clin Pract 2006; 60: 1654-1661
    CrossrefGoogle Scholar
  • 11 Barnett AH. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evid 2011; 6: 67-79
    Google Scholar
  • 12 Christensen M, Knop FK. Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?. Curr Diab Rep 2010; 10: 124-132
    CrossrefGoogle Scholar
  • 13 European public assessment report (EPAR) Byetta® (Exenatide). http://www.ema.europa.eu
    Google Scholar
  • 14 European public assessment report (EPAR) Victoza® (Liraglutid). http://www.ema.europa.eu
    Google Scholar
  • 15 Agerso H, Jensen LB, Elbrond B et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202
    CrossrefGoogle Scholar
  • 16 Fineman M, Flanagan S, Taylor K et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011; 50: 65-74
    CrossrefGoogle Scholar
  • 17 Matthews JE, Stewart MW, De Boever EH et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 4810-4817
    CrossrefGoogle Scholar
  • 18 Barrington P, Chien JY, Tibaldi F et al. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 2011; 13: 434-438
    CrossrefGoogle Scholar
  • 19 Malm-Erjefalt M, Bjornsdottir I, Vanggaard J et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 2010; 38: 1944-1953
    CrossrefGoogle Scholar
  • 20 Leiter LA, Carr MC, Stewart M et al. Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study. Diabetes Care 2014; 37: 2723-2730
    CrossrefGoogle Scholar
  • 21 Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 2006; 49: 706-712
    CrossrefGoogle Scholar
  • 22 Buse JB, Nauck M, Forst T et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013; 381: 117-124
    CrossrefGoogle Scholar
  • 23 Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47
    CrossrefGoogle Scholar
  • 24 Kapitza C, Forst T, Coester HV et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab 2013; 15: 642-649
    CrossrefGoogle Scholar
  • 25 Pratley RE, Nauck MA, Barnett AH et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014; 2: 289-297
    Google Scholar
  • 26 Fineman MS, Cirincione BB, Maggs D et al. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab 2012; 14: 675-688
    CrossrefGoogle Scholar
  • 27 Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885
    CrossrefGoogle Scholar
  • 28 Parkin CG, Brooks N. Is postprandial glucose control important? Is it practical in primary care settings?. Clinical Diabetes 2002; 20: 71-76
    CrossrefGoogle Scholar
  • 29 Relimpio F, Guerrero R, Martinez-Brocca MA. HbA1c levels are better predicted by prebreakfast than postbreakfast blood glucose self-analyses in type 2 diabetes. Influence of duration of diabetes and mode of treatment. Acta Diabetol 2007; 44: 55-59
    CrossrefGoogle Scholar
  • 30 Schrot RJ. Targeting plasma glucose: preprandial versus postprandial. Clinical Diabetes 2004; 22: 169-172
    CrossrefGoogle Scholar
  • 31 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes – Langfassung, 1. Auflage. Version 4. 2013, zuletzt geändert: November 2014. Available from: DOI: 10.6101/AZQ/000213 www.dm-therapie.versorgungsleitlinien.de [cited: 22.12.2014]
    Google Scholar
  • 32 Buse JB, Sesti G, Schmidt WE et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010; 33: 1300-1303
    CrossrefGoogle Scholar
  • 33 Dungan KM, Povedano ST, Forst T et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384: 1349-1357
    CrossrefGoogle Scholar
  • 34 Jonker D, Toft AD, Kristensen P et al. Pharmacokinetic Modelling of the Once-Daily Human GLP-1 Analogue Liraglutide in Healthy Volunteers and Comparison to Exenatide. Diabetes 2007; 56
    Google Scholar
  • 35 Watson E, Jonker DM, Jacobsen LV et al. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. J Clin Pharmacol 2010; 50: 886-894
    CrossrefGoogle Scholar
  • 36 Rosenstock J, Raccah D, Koranyi L et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 2013; 36: 2945-2951
    CrossrefGoogle Scholar
  • 37 Blevins T, Pullman J, Malloy J et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301-1310
    CrossrefGoogle Scholar
  • 38 Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250
    CrossrefPubMedGoogle Scholar
  • 39 DeYoung MB, MacConell L, Sarin V et al. Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011; 13: 1145-1154
    CrossrefGoogle Scholar
  • 40 Rosenstock J, Rodbard HW, Bain SC et al. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. J Diabetes Complications 2013; 27: 492-500
    CrossrefGoogle Scholar
  • 41 Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635
    CrossrefPubMedGoogle Scholar
  • 42 Neumiller JJ, Campbell RK. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2009; 43: 1433-1444
    CrossrefGoogle Scholar
  • 43 Ratner RE, Rosenstock J, Boka G et al. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010; 27: 1024-1032
    CrossrefGoogle Scholar
  • 44 Wang B, Zhong J, Lin H et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 2013; 15: 737-749
    CrossrefGoogle Scholar
  • 45 Pratley RE, Nauck M, Bailey T et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-1456
    CrossrefPubMedGoogle Scholar
  • 46 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015; 58: 429-442
    CrossrefGoogle Scholar
  • 47 DeVries JH, Bain SC, Rodbard HW et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012; 35: 1446-1454
    CrossrefPubMedGoogle Scholar